Abstract
A Surface Plasmon Resonance Imaging (SPRI) sensor has been developed for highly selective determination of cathepsin D (Cat D) or/and E (Cat E). The sensor contains immobilised pepstatin A, which binds aspartyl proteases from solution. Pepstatin A activated with N-Hydroxysuccinimide (NHS) and N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) was immobilized on an amine-modified gold surface. Cysteamine was used for modification of the gold surface. Pepstatin A concentration and pH of interaction were optimised. A concentration of pepstatin equal to 0.5 μg mL-1 and a pH of 3.75 were selected as optimal.The sensor's dynamic response range is between 0.25 and 1.0 ng mL-1, and the detection limit is 0.12 ng mL-1. However, the sensor cannot distinguish between Cat D and Cat E. In order to demonstrate the sensor's potential, Cat E was determined in human red blood cells, Cat D in human saliva, as well as total concentration of Cat D and Cat E in human nasal polyps.
Keywords: Biosensor, cathepsin D, cathepsin E, pepstatin A, Surface Plasmon Resonance Imaging
Protein & Peptide Letters
Title: SPR Imaging Biosensor for Aspartyl Cathepsins: Sensor Development and Application for Biological Material
Volume: 17 Issue: 9
Author(s): Ewa Gorodkiewicz and Elzbieta Regulska
Affiliation:
Keywords: Biosensor, cathepsin D, cathepsin E, pepstatin A, Surface Plasmon Resonance Imaging
Abstract: A Surface Plasmon Resonance Imaging (SPRI) sensor has been developed for highly selective determination of cathepsin D (Cat D) or/and E (Cat E). The sensor contains immobilised pepstatin A, which binds aspartyl proteases from solution. Pepstatin A activated with N-Hydroxysuccinimide (NHS) and N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide (EDC) was immobilized on an amine-modified gold surface. Cysteamine was used for modification of the gold surface. Pepstatin A concentration and pH of interaction were optimised. A concentration of pepstatin equal to 0.5 μg mL-1 and a pH of 3.75 were selected as optimal.The sensor's dynamic response range is between 0.25 and 1.0 ng mL-1, and the detection limit is 0.12 ng mL-1. However, the sensor cannot distinguish between Cat D and Cat E. In order to demonstrate the sensor's potential, Cat E was determined in human red blood cells, Cat D in human saliva, as well as total concentration of Cat D and Cat E in human nasal polyps.
Export Options
About this article
Cite this article as:
Gorodkiewicz Ewa and Regulska Elzbieta, SPR Imaging Biosensor for Aspartyl Cathepsins: Sensor Development and Application for Biological Material, Protein & Peptide Letters 2010; 17 (9) . https://dx.doi.org/10.2174/092986610791760450
DOI https://dx.doi.org/10.2174/092986610791760450 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Synthesis and Characterization of ROSA Dye - A Rhodamine B-type Fluorophore, Suitable for Bioconjugation and Fluorescence Studies in Live Cells
Protein & Peptide Letters Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Molecular Docking Studies of the Antitumoral Activity and Characterization of New Chalcone
Current Topics in Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Role of Metallothionein in Inflammatory Lung Diseases
Current Respiratory Medicine Reviews Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Current Molecular Pharmacology Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Rational Drug Design Paradigms: The Odyssey for Designing Better Drugs
Combinatorial Chemistry & High Throughput Screening